Objective: To evaluate the effect of Ridogrel enemas (Janssen Research Foundation, Beerse, Belgium) on disease activity and mucosal inflammatory mediators in patients with active left-sided ulcerative colitis. Design and methods: Eleven patients with active left-sided ulcerative colitis were evaluated in an open non-placebo-controlled pilot study. All patients were treated with Ridogrel enemas (300 mg/40 ml once daily) over four weeks. A disease activity score based on clinical, endoscopic and histological criteria was obtained before and after treatment with Ridogrel. The concentrations of thromboxane B2 (T×B2), prostaglandin E2 (PGE2), interleukin-6 (IL-6) and tumour necrosis factor α (TNF-α) were measured in mucosal biopsies before and after treatment. Results: One patient discontinued treatment because of progression of disease, the other ten patients tolerated the Ridogrel enemas well. Mucosal T×B2 concentration decreased significantly in all patients. The mucosal concentrations of the other inflammatory mediators (PGE2, IL-6 and TNF-α) were unaltered. The disease score decreased in five patients. However, clinical improvement was not always associated with a decrease in endoscopic and/or histological scores. Conclusions: This pilot study shows that Ridogrel enemas selectively reduce mucosal T×B2 concentration.

, , ,
doi.org/10.1097/00042737-200104000-00016, hdl.handle.net/1765/72110
European Journal of Gastroenterology and Hepatology
Department of Pharmacology

Auwerda, J., Zijlstra, F., Tak, C., van den Ingh, H. F. G. M., Wilson, P., & Ouwendijk, R. (2001). Ridogrel enemas in distal ulcerative colitis. European Journal of Gastroenterology and Hepatology, 13(4), 397–400. doi:10.1097/00042737-200104000-00016